• TaqI Restriction Endonuclease: Fast Protocols for DNA Digest

  2026-06-06

  TaqI Restriction Endonuclease addresses the need for rapid, sequence-specific DNA digestion in molecular biology, particularly for workflows involving plasmid mapping, PCR product analysis, and genomic DNA cleavage. The enzyme is optimized for fast, reliable sticky-end generation but should not be used for diagnostic or clinical applications where alternative specificities or methylation tolerance are required.

• Affinity-Purified Goat Anti-Rabbit IgG (H+L): Workflow Preci

  2026-06-05

  Unlock robust signal amplification in immunoassays with the HRP Goat Anti-Rabbit IgG (H+L) Antibody, an affinity-purified secondary delivering high specificity and versatility. This guide details optimized protocols, advanced use-cases, and troubleshooting strategies for Western blot, ELISA, and immunohistochemistry workflows.

• Cucurbitacin I (JSI-124): Protocols for STAT3-Targeted Cance

  2026-06-05

  Cucurbitacin I stands out as a selective STAT3 inhibitor pivotal for dissecting cancer cell signaling, proliferation, and invasion. This guide delivers advanced experimental workflows, troubleshooting strategies, and integration tips for leveraging Cucurbitacin I in both in vitro and in vivo oncology models.

• Pam3CSK4 TFA and Maternal-Neonatal Immunity: Beyond Protocol

  2026-06-04

  Explore how Pam3CSK4 TFA, a potent TLR1/2 agonist, advances our understanding of innate immune mechanisms and cytokine biomarkers in maternal-neonatal health. This article delivers deeper insight into translational assay design, highlighting novel findings on IL-17A and practical guidance for immunological research.

• Afatinib (BIBW 2992): Unlocking Advanced Tumor Assembloid Re

  2026-06-04

  Afatinib (BIBW 2992) enables irreversible, multi-targeted ErbB kinase inhibition in complex tumor models, empowering researchers to dissect resistance mechanisms and tumor–stroma interactions with greater physiological relevance. Recent gastric cancer assembloid advances and protocol optimizations reveal how Afatinib accelerates personalized therapy discovery.

• Honokiol Triggers Paraptosis in APL via MAPK/mTOR Pathways

  2026-06-03

  This study reveals that honokiol induces paraptosis-like cell death in acute promyelocytic leukemia (APL) cells through activation of mTOR and MAPK signaling. The findings clarify a caspase-independent death mechanism, suggesting new avenues for overcoming apoptosis resistance in leukemia therapy.

• Mycophenolic Acid as a Dehydrogenase Inhibitor: Precision To

  2026-06-03

  Explore how Mycophenolic acid functions as a dehydrogenase inhibitor and why its metabolic modulation is vital for next-generation immunology research. This article delivers new, protocol-focused insights and practical guidance for high-fidelity experimental design.

• iMSC-Exosomes Reprogram Macrophage Polarization in Disc Dege

  2026-06-02

  This study reveals that exosomes from human iPSCs-derived mesenchymal stem cells disrupt the pathological cycle between senescent nucleus pulposus cells and pro-inflammatory macrophages, mitigating intervertebral disc degeneration (IDD). The findings highlight metabolic reprogramming as a therapeutic target and provide a mechanistic basis for novel IDD interventions.

• Adenosine Triphosphate: Engine of Mitochondrial Metabolism I

  2026-06-02

  Adenosine triphosphate (ATP) is no longer merely the cell’s energy currency—it is the linchpin for metabolic regulation, signaling, and translational research. This article synthesizes mechanistic insight from recent mitochondrial discoveries, such as TCAIM’s post-translational control of a-ketoglutarate dehydrogenase, and provides strategic guidance for leveraging high-purity ATP (from APExBIO) to accelerate experimental design and disease modeling. Key protocol parameters and actionable outlooks are included.

• BMN 673 (Talazoparib): Potent PARP1/2 Inhibitor for DNA Repa

  2026-06-01

  BMN 673 (Talazoparib) is a highly potent and selective PARP1/2 inhibitor used in homologous recombination deficient cancer research. It demonstrates superior PARP-DNA complex trapping and cytotoxicity in DNA repair-deficient tumor models compared to other PARP inhibitors.

• MCC950 Sodium: Next-Gen NLRP3 Inhibition in Inflammatory Mod

  2026-06-01

  MCC950 sodium (CRID3 sodium salt) delivers unmatched selectivity and nanomolar potency for dissecting NLRP3-driven inflammation. Discover how this APExBIO reagent streamlines experimental autoimmune and sepsis models, with actionable protocol insights and troubleshooting strategies for robust inflammasome research.

• Exosomal SNORD52 Drives M2 Macrophage Polarization via JAK2/

  2026-05-31

  This study demonstrates that hepatoma cell-derived exosomal SNORD52 promotes M2 macrophage polarization by activating the JAK2/STAT6 pathway, revealing a novel mechanism in hepatocellular carcinoma (HCC) progression. These findings highlight the importance of snoRNA-mediated intercellular communication in the tumor microenvironment and suggest new avenues for immunomodulatory cancer research.

• Azilsartan Medoxomil Monopotassium: Pharmacology and Researc

  2026-05-30

  Explore the advanced pharmacology of Azilsartan medoxomil monopotassium, a highly selective AT1 antagonist pivotal in essential hypertension treatment research. This article uniquely bridges molecular mechanism with assay design, offering actionable insights for cardiovascular and renal studies.

• Panobinostat (LBH589): Quantitative Insights for Epigenetic

  2026-05-29

  Explore the quantitative impact of Panobinostat (LBH589) in epigenetic regulation and apoptosis induction in cancer cells. This article uniquely bridges mechanistic depth with assay optimization, offering practical guidance for translational research.

• Omeprazole (A2845): Technical Guide for H+,K+-ATPase Inhibit

  2026-05-29

  Omeprazole is a high-purity H+,K+-ATPase inhibitor optimized for research into gastric acid secretion and antiulcer mechanisms. It is best suited for workflows requiring precise modulation of gastric acid output in preclinical models. This compound should not be used for diagnostic or clinical purposes, and its workflow parameters require careful attention to solubility and stability.

641 records 13/43 page Previous Next First page 上5页 1112131415 下5页 Last page